ATNM
- Actinium Pharmaceuticals, Inc.
()
Overview
Company Summary
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing innovative targeted therapies for the treatment of various forms of cancer. The company specializes in the field of radiopharmaceuticals, which combines radiation therapy and pharmaceuticals to deliver targeted treatment directly to cancer cells.
Actinium's flagship product is called Iomab-B, which is designed to prepare patients for bone marrow transplant to treat hematologic malignancies, such as leukemia and lymphoma. Iomab-B targets and eliminates diseased blood cells in the bone marrow, which helps clear the path for a successful transplant.
In addition to Iomab-B, Actinium has a pipeline of other targeted therapies at various stages of development. These include Actimab-A, Actimab-M, and Actimab-MDS, among others. These therapies are designed to target antigens on cancer cells and deliver targeted radiation to destroy the cancer cells while minimizing damage to healthy tissues.
Actinium Pharmaceuticals also collaborates with leading research institutions and medical centers to further develop and optimize their therapies. The company's goal is to improve patient outcomes and quality of life by developing novel treatments for cancer that are more effective and have fewer side effects than traditional therapies.
Overall, Actinium Pharmaceuticals is dedicated to advancing the field of targeted cancer therapy and making a meaningful impact in the lives of patients with cancer.